External validation of the Intermountain Risk Scores for postdischarge thrombosis and bleeding in an independent population
4 affiliations
- 1Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Division of Hematology/Oncology, Department of Medicine, University of Vermont Medical Center, Burlington, Vermont, USA
- 2Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
- 3Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
- 4Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Division of Hematology/Oncology, Department of Medicine, University of Vermont Medical Center, Burlington, Vermont, USA; Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA
Abstract
Background: Extended thromboprophylaxis after medical hospitalization has not consistently shown benefit, largely due to increased bleeding events. Accurate prediction of postdischarge (PD) venous thromboembolism (VTE) and bleeding risk is therefore essential. The Intermountain Risk Scores (IMRSs) were developed to predict 90-day risks of these outcomes following discharge. Objectives: To assess the predictive performance and external validity of the IMRSs in an independent cohort. Methods: We retrospectively identified adults discharged alive from medical hospitalizations at an academic medical center between 2010 and 2019. PD VTE and bleeding events were identified using validated computable phenotypes. IMRSs were calculated using data at discharge, with missing data addressed via multiple imputation. We determined the observed risks of VTE and bleeding in our cohort for low- and high-risk patients and compared these with the corresponding risks reported in the original cohort and evaluated model discrimination by estimating the time-dependent area under the receiver operating characteristic curve. Results: Among 14,556 discharges, 108 PD VTE and 373 PD bleeding events occurred within 90 days. The observed risk for high-risk and low-risk categories was 0.9% and 0.5% for VTE (hazard ratio 1.51; 95% CI, 0.88-2.59) and 4.2% and 1.8% for bleeding (hazard ratio 2.51; 95% CI, 2.04-3.08), respectively. Discrimination was poor for both outcomes (area under the receiver operating characteristic curve 0.55 for VTE; 0.60 for bleeding). Conclusion: The IMRSs demonstrated limited discrimination in this external cohort. These findings suggest that the IMRSs may not be generalizable to all medical populations and highlight the need for more robust risk-stratification tools.
Related
- Development and internal validation of a nomogram for estimating concurrent superficial vein thrombosis at presentation in patients with lower extremity varicose veins
- Navigating neonatal thrombosis: contemporary insights into a complex disorder in a unique population
- Hypoxemia is an Independent Risk Factor for Perioperative Thrombosis at High Altitude: A Retrospective Study of 11,084 Patients
- Postanesthesia Care Unit Nausea, Postdischarge Nausea, and Quality of Recovery After Ambulatory Surgery
- Hypertension awareness, blood pressure severity, and all-cause mortality: independent analyses of population-based cohorts in China and the United States
BibTeX
@article{gergi2026external,
title = {{External validation of the Intermountain Risk Scores for postdischarge thrombosis and bleeding in an independent population}},
author = {Mansour Gergi and Katherine S. Wilkinson and Nicholas Roetker and Karlyn Martin and Allen B. Repp and Neil A. Zakai},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
month = aug,
doi = {10.1016/j.rpth.2026.106934},
url = {https://doi.org/10.1016/j.rpth.2026.106934},
note = {CC BY},
}
RIS
TY - JOUR
TI - External validation of the Intermountain Risk Scores for postdischarge thrombosis and bleeding in an independent population
AU - Mansour Gergi
AU - Katherine S. Wilkinson
AU - Nicholas Roetker
AU - Karlyn Martin
AU - Allen B. Repp
AU - Neil A. Zakai
PY - 2026
DA - 2026/08/01
JO - Research and Practice in Thrombosis and Haemostasis
DO - 10.1016/j.rpth.2026.106934
UR - https://doi.org/10.1016/j.rpth.2026.106934
AB - Background: Extended thromboprophylaxis after medical hospitalization has not consistently shown benefit, largely due to increased bleeding events. Accurate prediction of postdischarge (PD) venous thromboembolism (VTE) and bleeding risk is therefore essential. The Intermountain Risk Scores (IMRSs) were developed to predict 90-day risks of these outcomes following discharge. Objectives: To assess the predictive performance and external validity of the IMRSs in an independent cohort. Methods: We retrospectively identified adults discharged alive from medical hospitalizations at an academic medical center between 2010 and 2019. PD VTE and bleeding events were identified using validated computable phenotypes. IMRSs were calculated using data at discharge, with missing data addressed via multiple imputation. We determined the observed risks of VTE and bleeding in our cohort for low- and high-risk patients and compared these with the corresponding risks reported in the original cohort and evaluated model discrimination by estimating the time-dependent area under the receiver operating characteristic curve. Results: Among 14,556 discharges, 108 PD VTE and 373 PD bleeding events occurred within 90 days. The observed risk for high-risk and low-risk categories was 0.9% and 0.5% for VTE (hazard ratio 1.51; 95% CI, 0.88-2.59) and 4.2% and 1.8% for bleeding (hazard ratio 2.51; 95% CI, 2.04-3.08), respectively. Discrimination was poor for both outcomes (area under the receiver operating characteristic curve 0.55 for VTE; 0.60 for bleeding). Conclusion: The IMRSs demonstrated limited discrimination in this external cohort. These findings suggest that the IMRSs may not be generalizable to all medical populations and highlight the need for more robust risk-stratification tools.
SN - 2475-0379
ER -